Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > Sell... now if...
View:
Post by mercedesman on Dec 01, 2021 1:50pm

Sell... now if...

...you believe, as the market seems to believe (based on the current SP) , that there is almost ZERO (lets call it 2%) probablity of approval of PMX by the FDA.

This despite:
  • Phase 3B Trial being labelled "confirmatory" meaning they just have to reach the "meh" goals of Euphrates, but now armed with much better data and selection criteria.
  • indications from Mgt that the Tigris Trial, so far, is "exceeding expectations".
  • Favourable Trial paramaters granted by the FDA (Open label, Bayesian, 2:1)
  • likely far greater need now (Covid leads to Sepsis - see gut dysbiosis and endotoxemia in advanced/severe Covid patients)
  • 300,000 safe uses world-wide
  • Meta analysis data with 10's of thousands of participants supporting a PMX mortality benefit. 
  • Euphas 2 (early Trial stoppage for efficacy reasons)
  • Euphas Registry ( closing in on another decade of gathered evidence and proof)
  • PMX being supported by Ronco as a Golden Hour sequential therapy.  (Ronco is likley the world's leading authority on Sepsis, and AKI)
  • Kellum joins Spectral in 2021 (jettisoning all other ties with other co's including HP co's) Loads up on options and shares all above .425
  • mounting RWE evidence in support of PMX, and not just for Sepsis
  • it is backed by a multi billion dollar Japanese congolmerate
  • it has a distribution agreement with a multi-billion dollar Company that owns the ICU supply market.

And also sell, if despite all of the above, you believe that all of the following assets/pieces are totally worthless  to other market players as well:
  • Dialco = virtually worthless.  Even though it is likely (it's a question of when not if - per Seto)  to be the 3rd or 4th entrant in the about to greatly expand, HD market, with Diaco's entrant, offering "ground breaking" new technology
  • never mind that the first two entrants into the HD market, have captured a market cap of $ 2B USD for their Home Dialysis machine only
  • never mind that DIMI will smash most if not all barriers to adoption that the competition does not.
  • the FDA approved EAA is worthless despite its utility (at the very least) as a ICU triage tool to rule out Sepsis. And with worldwide exclusive rights to boot.
  • $ 80 million in past Trial costs, and acquired IP has no utility to other biotechs  (e.g. even just as a a tax loss shelter)
  • That they have valueless world wide & patented rights to the only HP pump on the market (SAMI) = utility for the Golden Hour sequntial therapy approach advocated by Ronco


MM
Comment by oilandgasman on Dec 01, 2021 2:31pm
If only they could sell the story, it's truely not their forte or have zero interest in the will of shareholders.
Comment by Domino55 on Dec 01, 2021 4:27pm
Is the valuation back up to a 2% probability of success? That is 50% higher than my own calculation. I'll go with yours. All salient points but as you know, no one capitalizes on their perceived shortcomings better.
Comment by mercedesman on Dec 01, 2021 4:39pm
I'm using a conservative valuation, and a valuation before factoring in the future Covid patients PMX revenue upside ;) .23 x X = 2% Solving for X X = .23/2% = $ 11.50 this is also an overly simplified, conservative equation, becasue the "failure" outcome is not = $0 for a two trick (actually really a 4- trick) pony. MM
Comment by Domino55 on Dec 01, 2021 5:24pm
Would it be asking too much that the company strive to value itself at a 10% probability of P3 success. Is that too long a stretch?
Comment by Accountprince on Dec 01, 2021 5:57pm
Dom - apparently it is asking too much of the company to strive to reach 10% of success value.  An issue done last year at 5% and one this year at 4%.  And according to Oilandgasman full disclosure by Seto recently on issue numbers to retail and to institutional - they know precisely who owns what.  Yet no comment when the price drops to less than 2%.  
Comment by Domino55 on Dec 01, 2021 6:16pm
A 10% valuation is a sizeable request given that it is a 5 bagger from here but it does still leave them a 90% probability of failure in the valuation to do whatever it is they do with it. At this late stage it is only fair to ask.
Comment by Revten on Dec 01, 2021 6:07pm
Hey MM I am still loading up pretty much Daily! Every time I ask myself where can I probably quadruple my money in the next 6-12 months? And guess what keeps coming up? The Complete List of reasons that you just posted! Its Insane how Great An Opportunity This Truly Is! For some reason I also keep noticing that Box that says "Significant Shareholder" when placing my Trades.... might ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities